The first 3D-bioprinting of an active brain tumor opens up new possibilities in the field of cancer research and drug development. The 3D-printed tumor has its own microenvironment, providing a testing ground for drugs with conditions as close to the human brain as possible. “Approximately 90% of all experimental drugs fail at the clinical stage because the success achieved in the lab is not reproduced in patients,” says Prof. Satchi-Fainaro, noting how the previous means of tumor testing were unsatisfactory. Read full article here
